Enlivex Therapeutics (ENLV) to Post Quarterly Earnings on Monday

Enlivex Therapeutics (NASDAQ:ENLV) is anticipated to announce its Q1 2026 results before the market opens on Monday, August 31st. Analysts expect Enlivex Therapeutics to post earnings of ($0.31) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, August 31, 2026 at 4:00 PM ET.

Enlivex Therapeutics Price Performance

Enlivex Therapeutics stock opened at $1.35 on Friday. The stock’s fifty day moving average price is $4.41 and its two-hundred day moving average price is $10.45. Enlivex Therapeutics has a one year low of $1.34 and a one year high of $27.15. The firm has a market cap of $23.61 million, a PE ratio of -0.16 and a beta of 1.60.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ENLV. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Finally, Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enlivex Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Institutional Investors Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of Enlivex Therapeutics during the 4th quarter valued at approximately $33,000. Invesco Ltd. bought a new position in Enlivex Therapeutics in the 4th quarter valued at approximately $43,000. XTX Topco Ltd lifted its stake in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares during the last quarter. Jane Street Group LLC boosted its position in Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Enlivex Therapeutics in the third quarter valued at approximately $57,000. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.